What GeneFrontier does

GeneFrontier Corporation is a Japanese biotechnology company founded on October 13, 2010, and headquartered in Kashiwa-shi, Chiba. It is a wholly-owned group company of KANEKA Corporation and operates in the protein engineering and biologics space. The company commercializes the PURE (Protein synthesis Using Recombinant Elements) system, originally invented by Professor Takuya Ueda at the University of Tokyo, through its flagship PUREfrex® product line — a portfolio of reconstituted cell-free protein synthesis kits (1.0, 2.0, 2.1, and 2.0 mini) and supplement modules (DnaK Mix, GroE Mix, DsbC Set, PDI Set, EF-P). These kits allow researchers to synthesize proteins in vitro in hours rather than days, with full control over reaction composition and the ability to produce difficult, toxic, or membrane-associated proteins that are challenging for cell-based systems.

The company also operates a custom monoclonal antibody service called Koutai Shokunin (抗体職人), using the HuCAL® Human Combinatorial Antibody Library licensed from MorphoSys AG for the Japanese market, and a proprietary ribosome display screening service (PUREfrex RD) that supports in vitro selection from gene libraries exceeding 10^12 diversity. GeneFrontier additionally maintains an internal drug discovery pipeline (GFC101 targeting CD69, GFC201 targeting ADAM28, GFC301 targeting ADAMTS4, and cyclic peptide programs against CTLA-4, Her2, EGFR, IL-6, and TNF-α), all currently in preclinical or R&D stages.

Commercially, GeneFrontier sells PUREfrex kits directly through its website in Japan and routes international sales exclusively through Cosmo Bio USA. Pricing ranges from entry-level kits at approximately $87 (100 µL) to large-scale 50 mL kits at 3,000,000 yen, with USD pricing available for overseas customers. The company reaches customers primarily through peer-reviewed publications, active participation in international scientific conferences (PEGS, PSSJ, MBSJ, SynBioBeta, iGEM), academic collaborations, and direct technical support. Its stated capital is 10 million yen, headcount is 11–50 employees, and no external funding rounds have been disclosed; growth has been financed by parent KANEKA Corporation and reinvested revenue.

Name

GeneFrontier

Legal name

GeneFrontier Corporation

Website

https://genefrontier.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

GeneFrontier Corporation is a Chiba, Japan-based biotech subsidiary of KANEKA Corporation that commercializes the PUREfrex® reconstituted cell-free protein synthesis platform and provides custom antibody and ribosome display screening services to academic and pharmaceutical researchers globally.

Ownership category

akta.pro rank

Product category

Cell-Free Protein Synthesis Reagents

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC), Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH), Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)

Keywords

• Cell-free protein synthesis
• Monoclonal antibody services
• Ribosome display screening
• Recombinant protein expression
• Biopharmaceutical drug discovery

Headquarters

HQ city

Chiba

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

1. Product Sales - Cell-Free Protein Synthesis Kits: Sale of PURE*frex*® kits in multiple sizes (100µL to 50mL reaction volumes) and versions (1.0, 2.0, 2.1, 2.0 mini) for cell-free protein synthesis. Also includes supplement products like DnaK Mix, GroE Mix, DsbC Set, PDI Set, and EF-P.
2. Custom Monoclonal Antibody Services (抗体職人): Fee-for-service custom monoclonal antibody development using HuCAL phage display technology for identifying antibodies against specific targets.
3. Ribosome Display Screening Services: Screening services using PURE*frex*® RD technology for discovering cyclic peptides, bispecific antibodies, and other biologics candidates.
4. Drug Discovery Pipeline: GeneFrontier develops proprietary drug candidates including GFC101 (CD69), GFC201 (ADAM28), GFC301 (ADAMTS4), and cyclic peptide programs targeting CTLA-4, Her2, EGFR, IL-6, TNF-α, and other targets.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

GeneFrontier develops and sells reconstituted cell-free protein synthesis kits (PUREfrex® 1.0, 2.0, 2.1, 2.0 mini) and supplement reagents (DnaK Mix, GroE Mix, DsbC Set, PDI Set, EF-P) for in vitro protein expression. The company also provides custom monoclonal antibody production services (Koutai Shokunin/Koutai Shokunin (抗体職人)) using licensed HuCAL® phage display technology, ribosome display screening services (PUREfrex RD) for biologics discovery, and operates an internal drug discovery pipeline targeting CD69, ADAM28, ADAMTS4, and cyclic peptide programs.

Product overview

GeneFrontier offers a portfolio of reconstituted cell-free protein synthesis kits (PUREfrex 1.0, 2.0, 2.1, 2.0 mini) and related supplements (DnaK Mix, GroE Mix, DsbC Set, PDI Set, EF-P) for in vitro protein expression, complemented by custom monoclonal antibody services (抗体職人/Koutai Shokunin) and ribosome display screening technology (PUREfrex RD) for drug discovery. The company also maintains an internal drug discovery pipeline with antibody and cyclic peptide programs.

Differentiator

Problem solved

Functional benefit

Products and services

• PUREfrex 1.0 Basic reconstituted cell-free protein synthesis kit based on the PURE system. Contains transcription/translation factors, ribosomes, amino acids, and NTPs for in vitro protein synthesis. Open composition platform designed for fundamental research with DTT as reducing agent. Available in 250µL, 2mL, 10mL, and 50mL reaction volumes.
• PUREfrex 2.0 High-yield version of the cell-free protein synthesis kit with improved reaction mixture composition. Platform designed for high-throughput expression and screening applications. Available in 250µL, 2mL, 10mL, and 50mL reaction volumes.
• PUREfrex 2.1 High-yield cell-free protein synthesis kit with flexible redox control. Specifically designed for disulfide-bonded proteins including scFv, Fab, VHH, and IgG. Solution I is subdivided to allow selection of suitable reducing agents. Available in 250µL, 2mL, 10mL, and 50mL reaction volumes.
• PUREfrex 2.0 mini Entry-level cell-free protein synthesis kit at 100 µL scale, providing an affordable option for beginners and small-scale protein synthesis experiments.
• DnaK Mix Molecular chaperone supplement containing purified E. coli DnaK, DnaJ, and GrpE. Improves solubility of aggregation-prone proteins and supports proper protein folding during cell-free synthesis. DnaK Mix addition increases luciferase activity approximately 6-fold. Available in 0.5mL, 10mL, and 50mL sizes.
• GroE Mix Molecular chaperone supplement containing purified E. coli GroEL and GroES. Assists in proper protein folding for proteins that are difficult to synthesize in active form. Available in 0.5mL, 10mL, and 50mL sizes.
• DsbC Set Disulfide bond formation supplement containing oxidized glutathione (GSSG) and E. coli DsbC disulfide isomerase. Enables synthesis of active proteins requiring correct disulfide bonds. Available in 0.5mL, 10mL, and 50mL sizes.
• PDI Set Disulfide bond formation supplement containing GSSG, human PDI (protein disulfide isomerase), and Ero1alpha. Allows controlled disulfide bond formation for human proteins. Available in 0.5mL, 10mL, and 50mL sizes.
• EF-P Elongation factor P supplement for synthesizing proteins containing consecutive proline residues. Post-translationally modified (beta-lysylated at Lys34) E. coli EF-P that improves translation efficiency of proline-rich proteins up to 2.1-fold. Available in 0.5mL, 10mL, and 50mL sizes.
• Koutai Shokunin (Custom Monoclonal Antibody Service) Fee-for-service custom monoclonal antibody production using HuCAL (Human Combinatorial Antibody Library) phage display technology licensed from MorphoSys AG. Enables animal-independent antibody selection capable of recognizing post-translational modifications, amino acid differences, and conformational epitopes. Achieves 90%+ success rate over recent 3 years.
• PUREfrex RD (Ribosome Display Screening Service) Ribosome display screening service based on customized PUREfrex technology with extremely low RNase contamination. Enables in vitro selection from gene libraries exceeding 10^12 diversity for discovering cyclic peptides, antibodies (scFv, Fab), and scaffolds for drug discovery. Affinity maturation has demonstrated approximately 60-fold improved EC50 versus original Fab.
• Drug Discovery Pipeline Proprietary drug discovery service developing antibody and peptide therapeutics. Pipeline includes GFC101 (targeting CD69, preclinical), GFC201 (targeting ADAM28, preclinical), GFC301 (targeting ADAMTS4, R&D), and multiple cyclic peptide programs targeting CTLA-4, Her2, EGFR, IL-6, and TNF-alpha. Potential revenue from licensing and royalties.
• PUREfrex Custom Kit Manufacturing Custom-manufactured PUREfrex kits allowing customers to order kits with customized composition of each solution. Quote-based ordering where price varies by reaction volume. OEM/embedded offering for specialized applications.

Quantifiable outcome

• 90%+ success rate over recent 3 years for antibody development projects
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Six partnerships are on record, tiered major, flagship and core.

• Tokyo Institute of Technology (東京工業大学)majorStrategic or Co-development Partner · 26 June 2023Collaborative research on N-terminal modification of cell-free synthesized proteins using PURE*frex*®. Demonstrated that post-translationally modified synthetic proteins can be localized to liposome membranes. Published in ACS Synthetic Biology.
• JAMSTEC (海洋研究開発機構)majorStrategic or Co-development Partner · 26 June 2023Three-way collaboration with Tokyo Institute of Technology on protein translation post-translational modifications using PURE*frex*®. Research on N-terminal acetylation and myristoylation published in ACS Synthetic Biology.
• PRISM BioLabflagshipStrategic or Co-development Partner · 4 January 2023Joint research collaboration on CTLA-4-binding cyclic peptides and peptidomimetic small molecules. Combined GeneFrontier's PURE*frex*® RD ribosome display technology with PRISM BioLab's PepMetics® peptide mimetic technology to generate small-molecule compounds with PPI inhibition activity against CTLA-4 (single-digit µM IC50 values). Published in Pharmaceuticals journal.
• MorphoSys AGcoreStrategic or Co-development PartnerMorphoSys AG has licensed their HuCAL® (Human Combinatorial Antibody Library) technology to GeneFrontier for the Japanese market. HuCAL technology represents cutting-edge synthetic antibody generation with billions of recombinant human Fab antibodies.
• University of Tokyo (東京大学)coreTechnology or IntegrationThe PURE system technology was invented by Professor Takuya Ueda at the University of Tokyo. GeneFrontier has developed PURE*frex*® based on this foundational technology. The collaboration enables GeneFrontier's exclusive access to optimized ribosome display applications.
• Cosmo Bio USAcoreChannel Partner/ Reseller/ DistributorAuthorized international distributor for GeneFrontier products outside Japan. Handles all international sales including quoting and order processing for PURE*frex*® kits and supplements worldwide.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Bio-Rad Laboratories: Bio-Rad provides protein research tools, including the SpectraMax and electrophoresis workflows, plus expression reagents. It overlaps with GeneFrontier in serving protein research customers though with a much broader product portfolio.
• Takara Bio: Takara Bio is a Japanese life sciences tools incumbent offering protein expression systems, antibody services, and cell-free expression reagents (e.g., Wheat Germ-based systems). It is a broad domestic incumbent competing for the same Japanese academic/biopharma customer pool.
• Thermo Fisher Scientific: Thermo Fisher offers a wide portfolio of protein expression and analysis tools through Invitrogen and Pierce brands, including cell-free and in vivo expression systems. It is a broad incumbent with overlapping tools for academic and pharma protein research customers.
• MorphoSys AG: MorphoSys is the licensor of the HuCAL® antibody library underlying GeneFrontier's Koutai Shokunin service and operates its own antibody discovery and development programs. It is both a strategic partner and a much larger antibody-discovery incumbent.

Direct peers

• New England Biolabs: NEB's PURExpress is a leading reconstituted cell-free protein synthesis kit and the most direct commercial analogue to GeneFrontier's PURE*frex*® platform. Both sell to academic and pharma protein research customers worldwide and compete on yield, scalability, and downstream applications.
• Creative Biolabs: Creative Biolabs provides custom antibody discovery services using phage display and other display technologies, directly overlapping with GeneFrontier's 'Koutai Shokunin' antibody service offering for biopharma clients.
• Biotechrabbit: Biotechrabbit markets cell-free protein synthesis kits and supplements (e.g., RTS) for academic and industrial protein expression. It overlaps with PURE*frex*® in target customer (academic/biotech labs) and use case (in vitro protein production).
• Promega: Promega offers cell-free protein expression systems (e.g., TNT®) and a broad portfolio of protein research reagents. It competes with GeneFrontier in protein synthesis and supports overlapping academic/biopharma workflows.
• CellFree Sciences: CellFree Sciences is also based on the PURE system technology originating from the University of Tokyo and offers cell-free protein synthesis tools. It is a head-to-head Japanese competitor with overlapping products and customer base.

Others

• Cosmo Bio: Cosmo Bio (parent of Cosmo Bio USA) is GeneFrontier's exclusive international distributor and a broader Japanese life sciences reagent supplier. It is a key channel partner and adjacent ecosystem participant rather than a direct technology competitor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/genefrontier-corp-

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GeneFrontier